Back to Journals » Therapeutics and Clinical Risk Management » Volume 9
New drug classes for the treatment of partial onset epilepsy: focus on perampanel
Authors Shih JJ, Tatum WO, Rudzinski LA
Received 8 April 2013
Accepted for publication 11 May 2013
Published 8 July 2013 Volume 2013:9 Pages 285—293
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Jerry J Shih,1 William O Tatum,1 Leslie A Rudzinski2
1Department of Neurology, Mayo Clinic, Jacksonville, FL, USA; 2Department of Neurology, Emory University, Atlanta, GA, USA
Abstract: Perampanel (2-[2-oxo-1-phenyl-5-pyridin-2-yl-1,2-dihydropyridin-3-yl] benzonitrile hydrate) is the latest in the line of new antiepileptic drugs with a novel mechanism of action. Perampanel inhibits α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-induced increases in intracellular Ca2+ and selectively blocks AMPA receptor-mediated synaptic transmission, thus reducing neuronal excitation. Three Phase III multicenter, randomized, double-blind, placebo-controlled trials demonstrated the efficacy and good tolerability of perampanel as adjunctive treatment in patients with refractory partial-onset seizures. The drug is approved for use in the European Union and United States, with expected release onto the American market in June–September 2013, pending US Drug Enforcement Agency classification. The pharmacology of perampanel offers potential as more than just another new antiepileptic drug. This first-in-class drug will provide another option for practitioners of rational polytherapy. As an AMPA-receptor antagonist, perampanel may possess antiepileptogenic properties in addition to its demonstrated antiseizure properties.
Keywords: perampanel, mechanism of action, efficacy, review
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.